Cumberland Pharmaceuticals Inc. (CPIX)
NASDAQ: CPIX · Real-Time Price · USD
6.57
+0.77 (13.28%)
Nov 18, 2026, 4:00 PM EST - Market closed
CPIX Revenue
Cumberland Pharmaceuticals had revenue of $2.16M in the quarter ending September 30, 2026, with 1,155.00% growth. In the year 2025, Cumberland Pharmaceuticals had annual revenue of $44.52M with 17.57% growth. That makes Cumberland Pharmaceuticals the 28,552nd largest company in the world by revenue and 3,826th in the United States.
Revenue (ttm)
$44.52M
Revenue Growth
+17.57%
P/S Ratio
2.13
Revenue / Employee
$526,010
Employees
88
Market Cap
98.50M
Revenue by Geography
- United States 39.62M 89.0%
- China 2.98M 6.7%
- South Korea 1.32M 3.0%
- Russia 429.19K 1.0%
- Mexico 120.00K 0.3%
- Australia 31.46K 0.1%
- Saudi Arabia 13.00K 0.0%
- Other Outside The United States 9.28K 0.0%
Fiscal year ended Dec 31, 2025 See the full CPIX breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 44.52M | 6.65M | 17.57% |
| Dec 31, 2024 | 37.87M | -1.68M | -4.26% |
| Dec 31, 2023 | 39.55M | -2.46M | -5.85% |
| Dec 31, 2022 | 42.01M | 6.03M | 16.75% |
| Dec 31, 2021 | 35.99M | -1.46M | -3.89% |
| Dec 31, 2020 | 37.44M | 3.05M | 8.88% |
| Dec 31, 2019 | 34.39M | 5.04M | 17.19% |
| Dec 31, 2018 | 29.34M | -11.81M | -28.69% |
| Dec 31, 2017 | 41.15M | 8.12M | 24.60% |
| Dec 31, 2016 | 33.03M | -493.49K | -1.47% |
| Dec 31, 2015 | 33.52M | -3.38M | -9.17% |
| Dec 31, 2014 | 36.90M | 4.87M | 15.22% |
| Dec 31, 2013 | 32.03M | -16.82M | -34.44% |
| Dec 31, 2012 | 48.85M | -2.29M | -4.48% |
| Dec 31, 2011 | 51.14M | 5.27M | 11.48% |
| Dec 31, 2010 | 45.88M | 2.34M | 5.37% |
| Dec 31, 2009 | 43.54M | 8.46M | 24.13% |
| Dec 31, 2008 | 35.08M | 7.01M | 24.98% |
| Dec 31, 2007 | 28.06M | 10.25M | 57.52% |
| Dec 31, 2006 | 17.82M | 7.13M | 66.66% |
| Dec 31, 2005 | 10.69M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Organogenesis Holdings | 352.05M |
| Organigram Global | 217.71M |
| Akebia Therapeutics | 197.20M |
| Glass House Brands | 176.98M |
| InterCure | 84.76M |
| Journey Medical | 69.52M |
| BGM Group | 47.90M |
| Zhengye Biotechnology Holding | 15.45M |
CPIX News
- 7 days ago - Cumberland Pharmaceuticals Slides: Corporate presentation - Filings
- 8 days ago - Cumberland Pharmaceuticals Earnings Call Transcript: Q3 2026 - Transcripts
- 8 days ago - Cumberland Pharmaceuticals Earnings release: Q3 2026 - Filings
- 8 days ago - Cumberland Pharmaceuticals Quarterly report: Q3 2026 - Filings
- 8 days ago - CUMBERLAND PHARMACEUTICALS REPORTS Q3 2026 FINANCIAL RESULTS & COMPANY UPDATE - PRNewsWire
- 13 days ago - CPIX Investors Have Opportunity to Join Cumberland Pharmaceuticals Inc. Fraud Investigation with SBS Law - Business Wire
- 15 days ago - CUMBERLAND PHARMACEUTICALS TO ANNOUNCE COMPANY UPDATE & Q3 2026 FINANCIAL RESULTS - PRNewsWire
- 23 days ago - Cumberland plans to file NDA for ifetroban in DMD - TheFly